Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery is unknown. In this phase 3 trial, we randomly ...

In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the ...

BARCELONA, Spain — Adding pembrolizumab to standard concurrent chemoradiotherapy (CCRT) significantly improves overall survival in patients with high-risk, locally advanced cervical cancer ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA's decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC).

Monday, Bristol Myers Squibb & Co (NYSE:BMY) released data from the cohorts of the Phase 1/ 2 KRYSTAL-1 study evaluating Krazati (adagrasib) in combination with cetuximab for previously treated ...

In the phase III study, ivonescimab achieved a median PFS of 11.14 months compared with 5.82 months with pembrolizumab, translating into a 49% reduction in the risk of progression or death (HR 0. ...

Meanwhile, 43% of patients treated with adagrasib experienced serious treatment ... Krazati plus Merck & Co's PD-1 inhibitor Keytruda (pembrolizumab), reported earlier this month, showed a 49% ...

After a median follow-up of 75 months, the 5-year OS was 86.6% in patients who received pembrolizumab (Keytruda) before and after surgery compared with 81.7% in those who received only neoadjuvant ...